Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CALCRLCHRM1CHRM2CHRM3F2RMAOAMAOBMAP2K1MAP2K2NTRK1NTRK2NTRK3OPRD1OPRK1OPRM1P2RY12PKLRSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC18A2SLC6A2SLC6A3TLR7TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8dacAdacBdacCfolAftsImrcAmrcBmrdApolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmB1rpmB2rpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsR1rpsR2rpsSrpsTrpsUrpsZykgMykgO
The experimentally established mechanism targets of Cysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.80 |
| ▸ | ENPEP | Q07075 | 6/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.43 |
| ▸ | GSR | P00390 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL11127428 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11ENPEPPMP22GSR | |
| Cysteine SCHEMBL431234 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11ENPEPPMP22GSR | |
| Cysteine SCHEMBL11127430 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11ENPEPPMP22GSR | |
| Cysteine SCHEMBL28607761 | 0.98 | PTGS1 (0.76) | PTGS1SLC7A11ENPEPPMP22GSR | |
| Cysteine SCHEMBL7728523 | 0.98 | PTGS1 (0.76) | PTGS1SLC7A11ENPEPPMP22GSR | |
| Cysteine SCHEMBL28996192 | 0.98 | PTGS1 (0.76) | PTGS1SLC7A11ENPEPPMP22GSR | |
| Cysteine SCHEMBL8817342 | 0.98 | PTGS1 (0.76) | PTGS1SLC7A11ENPEPPMP22GSR | |
| Cysteine SCHEMBL8817362 | 0.98 | PTGS1 (0.76) | PTGS1SLC7A11ENPEPPMP22GSR | |
| Cysteine SCHEMBL8817347 | 0.98 | PTGS1 (0.76) | PTGS1SLC7A11ENPEPPMP22GSR | |
| Cysteine SCHEMBL29009435 | 0.93 | PTGS1 (0.70) | PTGS1SLC7A11ENPEPPMP22GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-4359560-B1 | MULTIRESIDUAL METHOD FOR DETECTING AND/OR QUANTIFYING AMINO ACIDS, ORGANIC ACIDS AND/OR MODIFIED NUCLEOTIDES BY MEANS OF HILIC CHROMATOGRAPHIC SEPARATION AND MS/MS | CRESCENDO CARE S R L (IT) | 2025-05-07 | — | — | EP | claimed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | claimed |
| US-20240426830-A1 | CHRONIC WOUND HEALING BIOMARKER DIAGNOSTICS | THE TRUSTEES OF INDIANA UNIVERSITY | 2024-12-26 | — | — | US | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| US-20240288409-A1 | MULTIRESIDUAL METHOD FOR DETECTING AND/OR QUANTIFYING AMINO ACIDS, ORGANIC ACIDS AND/OR MODIFIED NUCLEOTIDES BY MEANS OF HILIC CHROMATOGRAPHIC SEPARATION AND MS/MS | CRESCENDO CARE S.R.L. (IT) | 2024-08-29 | — | — | US | claimed |
| WO-2023126758-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2023-07-06 | — | — | WO | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| WO-2023069598-A1 | CHRONIC WOUND HEALING BIOMARKER DIAGNOSTICS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-04-27 | — | — | WO | claimed |
| US-20210364526-A1 | METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLOMIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| CN-104190362-B | A kind of preparation method of the composite that contains cysteine and ferrous compound | TIANJIN UNIVERSITY OF TECHNOLOGY (CN) | 2016-05-18 | — | — | CN | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| CN-104190362-A | Preparation method of composite material containing cysteine and ferrous compound | UNIV TIANJIN TECHNOLOGY | 2014-12-10 | — | — | CN | claimed |
| EP-1641351-B1 | COMPOSITIONS AND METHODS FOR DECREASING AGE-RELATED DETERIORATION IN MENTAL ACTIVITIES IN COMPANION ANIMALS | HILLS PET NUTRITION INC (US) | 2014-06-04 | — | — | EP | claimed |
| US-20030162732-A1 | Combination of aminosugars and cysteine or cysteine derivatives | ASTION DEVELOPMENT A/S (DK) | 2003-08-28 | — | — | US | claimed |
| US-20030158118-A1 | Combination of cimetidine and cysteine derivatives for treating cancer | WEIDNER MORTEN SLOTH (DK) | 2003-08-21 | — | — | US | claimed |
| WO-2003045359-A2 | COMBINATION OF CIMETIDINE AND CYSTEINE DERIVATIVES FOR TREATING CANCER | ASTION ONCOLOGY APS (DK) | 2003-06-05 | — | — | WO | claimed |
| WO-2003002125-A2 | COMBINATION OF AMINOSUGARS AND CYSTEINE OR CYSTEINE DERIVATIVES | ASTION A/S (DK) | 2003-01-09 | — | — | WO | claimed |
| US-4396763-A | ANTITUMOR AGENTS | MEIJI MILK PRODUCTS COMPANY LIMITED (JP) | 1983-08-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162732-A1 | Combination of aminosugars and cysteine or cysteine derivatives | CBS, CTH, AADAT | PTGS1 114/4885SLC7A11 7/4885ENPEP 70/4885 |
| US-20030158118-A1 | Combination of cimetidine and cysteine derivatives for treating cancer | MGMT, CMA1, CYSLTR2 | PTGS1 33/4885SLC7A11 61/4885ENPEP 193/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | PTGS1 2333/4885SLC7A11 130/4885ENPEP 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.